/

Sociétés

Sh

Non vérifié

Shorla Oncology

Ce que nous écrivons

Hygiène alimentaireIndustrieIndustrie pharmaceutiqueOncologieSanté

6 communiqués de presse

Voir tous les communiqués de presse

15/07/2025

Industrie

Hygiène alimentaire

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

Science

Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid

Source

Shorla Oncology

Émetteur

1.00

0

29/04/2025

Shorla Oncology Announces FDA Approval of TEPYLUTE® 100mg, First and Only Ready-to-Dilute Multi-Dose Vial of Thiotepa to Treat Breast and Ovarian Cancer and Commercial Launch of TEPYLUTE 15mg and 100mg Vials in the U.S.

Source

Shorla Oncology

Émetteur

1.00

0

04/03/2025

Shorla Oncology Announces Expansion of U.S. Commercial Footprint with Launch of Dedicated Sales Force and Market Access Teams

Source

Shorla Oncology

Émetteur

1.00

0

25/11/2024

Multimédia

Industrie

Hygiène alimentaire

Industrie pharmaceutique

Santé

Oncologie

Shorla Oncology Announces FDA Approval of IMKELDI (imatinib) Oral Solution, an Oral Liquid for the Treatment of Certain Forms of Leukemia and Other Cancers

Source

Shorla Oncology

Émetteur

1.00

0

29/10/2024

Shorla Oncology Announces U.S. Food and Drug Administration (FDA) Expanded Approval of JYLAMVO™ (methotrexate), an Oncology and Autoimmune Drug for Pediatric Indications

Source

Shorla Oncology

Émetteur

1.00

0

28/06/2024

Industrie

Hygiène alimentaire

Santé Publique

Santé

Industrie pharmaceutique

Oncologie

Science

Shorla Oncology Announces FDA Approval for TEPYLUTE, A Novel Formulation to Treat Breast and Ovarian Cancer

Source

Shorla Oncology

Émetteur

1.00

0

Followers

0

Compatibilité

0